Becton, Dickinson and Company (BD) has introduced the new following 510(k) clearance from the US Food and Drug Administration (FDA).
Designed to be compatible with integrated catheters, the new needle-free blood draw technology is said to further enable BD鈥檚 ‘One-Stick Hospital Stay鈥� vision.
The device comes with design enhancements to attain compatibility with integrated and long peripheral IV catheters, including the new Nexiva Closed IV Catheter System with NearPort V Access.
This builds upon PIVO’s existing compatibility with traditional short peripheral IV catheters introduced in 2017.
With the capacity to draw blood samples directly from a patient’s peripheral IV line using PIVO Pro, the new solution integrates the clinical benefits demonstrated by the integrated closed Nexiva Catheter System.
These benefits include reduced catheter complications and longer dwell times.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBD Medication Delivery Solutions worldwide president Eric Borin said: 鈥淭he latest innovation to our PIVO portfolio helps expand needle-free blood collection to even more patients and clinicians as we continue to redefine the standard of care through our ‘One-Stick Hospital Stay’ vision.
鈥淭his new solution helps to reduce unnecessary and repeat needlesticks in the hospital while elevating clinical outcomes, improving workflow and creating a better experience for clinicians and patients.鈥�
In July 2023, the FDA granted 510(k) clearance for the updated BD Alaris Infusion System.
The approval included the latest hardware advancements for point-of-care units, patient-controlled analgesia pumps, large volume pumps, syringe pumps and respiratory monitoring and auto-identification modules.
